Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
E-pub ahead of print

The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Use of prescription drugs in the older adult population-a nationwide pharmacoepidemiological study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Obesity-induced CYP2E1 activity in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Arterial spin labeling: a technical overview

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

PURPOSE: A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).

METHODS: We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation.

RESULTS: The infliximab biosimilar constituted 90.6% of the total amount of infliximab four months following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds.

CONCLUSION: We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.

Original languageEnglish
JournalEuropean Journal of Clinical Pharmacology
ISSN0031-6970
DOIs
Publication statusE-pub ahead of print - 1 Nov 2019

ID: 58296606